Duopharma Biotech Total Asset vs. Return On Equity
| 7148 Stock | 1.25 0.01 0.81% |
For Duopharma Biotech profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Duopharma Biotech to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Duopharma Biotech Bhd utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Duopharma Biotech's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Duopharma Biotech Bhd over time as well as its relative position and ranking within its peers.
Duopharma |
Duopharma Biotech Bhd Return On Equity vs. Total Asset Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Duopharma Biotech's current stock value. Our valuation model uses many indicators to compare Duopharma Biotech value to that of its competitors to determine the firm's financial worth. Duopharma Biotech Bhd is number one stock in total asset category among its peers. It also is number one stock in return on equity category among its peers . The ratio of Total Asset to Return On Equity for Duopharma Biotech Bhd is about 106,493,253 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Duopharma Biotech's earnings, one of the primary drivers of an investment's value.Duopharma Return On Equity vs. Total Asset
Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.
Duopharma Biotech |
| = | 1.16 B |
Total Asset is typically divided on the balance sheet on current asset and long-term asset. Long-term is the value of company property and other capital assets that are expected to be useable for more than one year. Long term assets are reported net of depreciation. On the other hand current assets are assets that are expected to be sold or converted to cash as part of normal business operation.
Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Duopharma Biotech |
| = | 10.93 |
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
Duopharma Return On Equity Comparison
Duopharma Biotech is currently under evaluation in return on equity category among its peers.
Duopharma Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Duopharma Biotech. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Duopharma Biotech position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Duopharma Biotech's important profitability drivers and their relationship over time.
Use Duopharma Biotech in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Duopharma Biotech position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Duopharma Biotech will appreciate offsetting losses from the drop in the long position's value.Duopharma Biotech Pair Trading
Duopharma Biotech Bhd Pair Trading Analysis
The ability to find closely correlated positions to Duopharma Biotech could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Duopharma Biotech when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Duopharma Biotech - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Duopharma Biotech Bhd to buy it.
The correlation of Duopharma Biotech is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Duopharma Biotech moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Duopharma Biotech Bhd moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Duopharma Biotech can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Duopharma Biotech position
In addition to having Duopharma Biotech in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Large Blend Funds Thematic Idea Now
Large Blend Funds
Fund or Etfs that invest in stocks of large organizations that have characteristics of both growth and value companies. The Large Blend Funds theme has 37 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Large Blend Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Duopharma Stock
To fully project Duopharma Biotech's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Duopharma Biotech Bhd at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Duopharma Biotech's income statement, its balance sheet, and the statement of cash flows.